Delivering on the Potential of mRNA Therapeutics
Publication
Article
Pharmaceutical TechnologyThe Real Message Behind Commercial mRNA Products, April 2023 eBook
Volume 2023 eBook
Issue 3
Pages: 26–34
The complexity of the RNA production process creates challenges.
Christoph Burgstedt - Stock.adobe.com
RNA has been likened to software; once a delivery method is discovered, the sequence can be changed to produce any protein in the body. However, the apparent simplicity of the principle belies the complexity of the production process, and many challenges remain.
Messenger RNA (mRNA) prophylactic vaccines achieved major breakthroughs during the COVID-19 pandemic, gaining approval in more than 150 countries. The speed with which these vaccines were taken to market was a testament to the drive of the innovators, suppliers, and regulatory bodies involved. Now that the general principle is proven, there is much work to do to fully exploit the potential of mRNA in non-COVID infectious diseases, such as immuno-oncology, auto-immune diseases, protein replacement therapies, and gene-editing, to name but a few applications.
Read this article in Pharmaceutical Technology’s The Real Message Behind Commercial mRNA Products eBook.
About the authors
David Ricketts is director of Business Development; Nevin Witman is a consultant for etherna; Phil Challis is VP Product Development; Senne Dillen is senior scientist Drug Substance and Drug Product Development; and Bernard Sagaert is interim CEO, all with etherna.
Article details
Pharmaceutical Technology
eBook: The Real Message Behind Commercial mRNA Products
April 2023
Pages: 26–34
Citation
When referring to this article, please cite it as Ricketts, D.; Witman, N.; Challis, P.; Dillen, S.; Sagaert, B. Delivering on the Potential of mRNA Therapeutics. Pharmaceutical Technology's The Real Message Behind Commercial mRNA Products eBook (April 2023).
Articles in this issue
Stability in mRNA-LNP Formulations
Nucleic Acid-based Therapeutics Are Stepping into the Spotlight
Learning to Think at Lightspeed
Managing mRNA Instability
The Role of Separation Techniques in the Analysis of mRNA Therapeutic Drug Substances and Drug Products
The Marriage of RNA and Mass Spectrometry
Delivering on the Potential of mRNA Therapeutics
The COVID-19 Pandemic and Its Positive Impact on RNA Drug Development
Recent Videos
Related Content
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024Podcast
In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development
March 26th 2024Podcast
In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.
